Takumida, Hiroshi http://orcid.org/0000-0001-9903-1402
Horinouchi, Hidehito http://orcid.org/0000-0001-9090-801X
Masuda, Ken
Shinno, Yuki
Okuma, Yusuke http://orcid.org/0000-0001-5743-0149
Yoshida, Tatsuya
Goto, Yasushi
Yamamoto, Noboru http://orcid.org/0000-0002-0787-2851
Ohe, Yuichiro http://orcid.org/0000-0002-6137-073X
Article History
Received: 6 June 2021
Accepted: 4 August 2021
First Online: 14 August 2021
Declarations
:
: Dr. Takumida has nothing to disclose. Dr. Horinouchi reports grants and personal fees from MSD, personal fees from Lilly, grants and personal fees from AstraZeneca, grants and personal fees from BMS, grants and personal fees from Ono, personal fees from Merck Biopharma, grants from Daiichi-Sankyo, grants from AbbVie, grants and personal fees from Janssen, grants from Genomic Health, grants and personal fees from Chugai, personal fees from Kyowa-Kirin, and personal fees from Nihonkayaku, outside the submitted work. Dr. Masuda reports personal fees from Chugai and personal fees from AstraZeneca, outside the submitted work. Dr. Shinno reports personal fees from Pfizer, personal fees from AstraZeneca, personal fees from Chugai Pharmaceutical, grants from Japan Clinical Research Operations K.K., grants from Janssen Pharmaceutical K.K., and grants from Ono Pharmaceutical, outside the submitted work. Dr. Okuma reports grants from AbbVie G.K., personal fees from Astra Zeneca, grants and personal fees from Chugai, and personal fees from Eli Lilly, outside the submitted work. Dr. Yoshida reported receiving grants and personal fees from AstraZeneca, grants and personal fees from Bristol-Myers Squibb, AbbVie, Merck Sharp & Dohme, Ono Pharmaceutical, and Chugai, personal fees from Novartis, Taiho Pharmaceutical, Eli Lilly, Boehringer Ingelheim, Roche Diagnostics, and Archer, and grants from Takeda Pharmaceutical outside the submitted work. Dr. Goto reports grants and personal fees from Eli Lilly, personal fees from Chugai, grants and personal fees from Taiho Pharmaceutical, personal fees from Boehringer Ingelheim, grants and personal fees from Pfizer, grants and personal fees from Novartis, personal fees from AstraZeneca, grants and personal fees from MSD, grants and personal fees from Guardant Health, grants and personal fees from Ono Pharmaceutical, grants from Kyorin, grants and personal fees from Daiichi Sankyo, personal fees from Illumina, and grants and personal fees from Bristol-Myers Squibb, outside the submitted work. Dr. Yamamoto reports grants from Chugai, grants from Taiho, grants from Eisai, grants from Lilly, grants from Quintiles, grants from Astellas, grants from BMS, grants from Novartis, grants from Daiichi-Sankyo, grants from Pfizer, grants from Boehringer Ingelheim, grants from Kyowa-Hakko Kirin, grants from Bayer, grants from Ono Pharmaceutical Co., Ltd., grants from Takeda, personal fees from Ono Pharmaceutical Co., Ltd., personal fees from Chugai, personal fees from AstraZeneca, personal fees from Pfizer, personal fees from Lilly, personal fees from BMS, personal fees from Eisai, personal fees from Otsuka, personal fees from Takeda, personal fees from Boehringer Ingelheim, personal fees from Cimic, grants from Janssen Pharma, grants from MSD, grants from Merck, personal fees from Sysmex, grants from GSK, grants from Sumitomo Dainippon, grants from Chiome Bioscience Inc., grants from Otsuka, and grants from Carna Biosciences, outside the submitted work. Dr. Ohe reports grants and personal fees from AstraZeneca, grants and personal fees from Chugai, grants and personal fees from Ono, grants and personal fees from BMS, grants and personal fees from Kyorin, personal fees from Celltrion, personal fees from Amgen, personal fees from Nippon Kayaku, grants and personal fees from Eli Lilly, personal fees from Boehringer Ingelheim, personal fees from Bayer, grants and personal fees from Pfizer, personal fees from MSD, grants and personal fees from Taiho, personal fees from Kyowa Hakko Kirin, grants from Dainippon-Sumitomo, grants from Novartis, grants from Ignyta, grants from Takeda, grants from Kissei, grants from Daiichi-Sankyo, grants from Janssen, and grants from Loxo, outside the submitted work.
: This study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the Certified Review Board of the National Cancer Center Hospital (2015–355). Patients were provided with an information disclosure document explaining the study and were excluded from the analysis if they opted out.